Advertisement

Obesity Surgery

, Volume 28, Issue 6, pp 1766–1774 | Cite as

Implanted Closed-Loop Gastric Electrical Stimulation (CLGES) System with Sensor-Based Feedback Safely Limits Weight Regain at 24 Months

  • S. Morales-Conde
  • I. Alarcón del Agua
  • L. Busetto
  • F. Favretti
  • M. Anselmino
  • G. M. Rovera
  • M. Socas-Macias
  • A. Barranco-Moreno
  • R. Province-Azalde
  • A. J. Torres
Original Contributions
  • 118 Downloads

Abstract

Background

Weight regain following bariatric surgery is not uncommon. Safe, effective weight loss treatment up to 1 year has been reported with the closed-loop gastric electrical stimulation (CLGES) system. Continuous recording of eating and activity behavior by onboard sensors is one of the novel features of this closed-loop electrical stimulation therapy, and may provide improved long-term weight maintenance by enhancing aftercare.

Methods

Four centers participating in a 12-month prospective multicenter randomized study monitored all implanted participants (n = 47) up to 24 months after laparoscopic implantation of a CLGES system. Weight loss, safety, quality of life (QOL), and cardiac risk factors were analyzed.

Results

Weight regain was limited in the 35 (74%) participants remaining enrolled at 24 months. Mean percent total body weight loss (%TBWL) changed by only 1.5% between 12 and 24 months, reported at 14.8% (95% CI 12.3 to 17.3) and 13.3% (95% CI 10.7 to 15.8), respectively. The only serious device-/procedure-related adverse events were two elective system replacements due to lead failure in the first 12 months, while improvements in QOL and cardiovascular risk factors were stable thru 24 months.

Conclusion

During the 24 month follow-up, CLGES was shown to limit weight regain with strong safety outcomes, including no serious adverse events in the second year. We hypothesize that CLGES and objective sensor-based behavior data combined to produce behavior change. The study supports CLGES as a safe obesity treatment with potential for long-term health benefits.

Trial registration

ClinicalTrials.gov identifier: NCT01448785

Keywords

Obesity Morbid obesity Gastric stimulation Eating behavior Weight loss 

Notes

Acknowledgements

We would like to acknowledge the following investigators and site personnel who participated in the study: Investigators are as follows: Spain—Salvador Morales Conde, MD, Isaías Alarcón del Agua MD, Hospital Virgen del Rocio, Sevilla; Antonio José Torres, MD, Andrés Sanchez Pernaute, MD, Miguel A. Rubio, MD, Complutense University of Madrid Hospital Clinico “San Carlos”, Madrid; Antonio José Torres, Fernando Lapuente, Felipe Acedo, Antonio Picardo, Hospital Universitario Madrid Monteprincipe, Madrid. Italy—Franco Favretti, MD, Vicenza Regional Hospital, Vicenza; Giuseppe M. Rovera MD, San Luca Torino, Torino; Marco Anselmino MD, University Hospital Pisa, Pisa.

We would also like to thank sponsor personnel Javier Sanchez and Ksenija Mlinar for the support with device programming and data collection.

Funding Information

The study was financially supported by IntraPace Inc., San Jose, CA, USA.

Compliance with Ethical Standards

Informed consent was obtained from all individual participants included in the study.

The study was conducted in accordance with Good Clinical Practice and consistent with the Declaration of Helsinki.

Conflict of Interest

Authors 1, 2, 4, 5, 6, 7, and 8 have nothing to disclose. Author 3 reports personal fees from IntraPace Inc., during the conduct of the study; and personal fees from Novo Nordisk, outside the submitted work. Authors 9 and 10 report personal fees from IntraPace Inc., during the conduct of the study.

References

  1. 1.
    Fung M, Wharton S, Macpherson A, et al. Receptivity to bariatric surgery in qualified patients. J Obes. 2016;2016:6.CrossRefGoogle Scholar
  2. 2.
    Abell TL, Chen J, Emmanuel A, et al. Neurostimulation of the gastrointestinal tract: review of recent developments. Neuromodulation. 2015;18(3):221–227; discussion 227.  https://doi.org/10.1111/ner.12260.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shikora SA, Wolfe BM, Apovian CM, et al. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the ReCharge trial. J Obes. 2015;2015:365604.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & bariatric surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Surg Obes Relat Dis. 2008;4(5 Suppl):S109–84.  https://doi.org/10.1016/j.soard.2008.08.009.CrossRefPubMedGoogle Scholar
  5. 5.
    Burke LE, Wang J, Sevick MA: Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc 2011, 111(1):92–102, 1, DOI:  https://doi.org/10.1016/j.jada.2010.10.008.
  6. 6.
    Horbach T, Meyer G, Morales-Conde S, Alarcón del Agua I, Favretti F, Anselmino M, Rovera G, Dargent J, Stroh C, Susewind M et al: Multicenter randomized study of closed-loop gastric electrical stimulation versus laparoscopic adjustable gastric band for the treatment of obesity. Int J Obes 2016, 40 (12):1891–1898, DOI:  https://doi.org/10.1038/ijo.2016.159.
  7. 7.
    Stunkard A, Messick S. Eating inventory: manual. San Antonio, TX: Pearson Education, Inc.; 1988.Google Scholar
  8. 8.
    Kolotkin RL, Norquist JM, Crosby RD, et al. One-year health-related quality of life outcomes in weight loss trial participants: comparison of three measures. Health Qual Life Outcomes. 2009;7(1):53.  https://doi.org/10.1186/1477-7525-7-53.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gillett MJ: International expert committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334. The Clinical biochemist Reviews 2009, 30(4):197–200.Google Scholar
  10. 10.
    Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(2):269–93.  https://doi.org/10.4158/EP.18.2.269.CrossRefPubMedGoogle Scholar
  11. 11.
    Allergan: Summary of safety and effectiveness, LAP-BAND® Adjustable Banding system In.; 2010.Google Scholar
  12. 12.
    Ethicon Endo-Surgery I: Summary of safety and effectiveness data, REALIZE adjustable gastric band. In.; 2007.Google Scholar
  13. 13.
    Stevens J, Truesdale KP, McClain JE, et al. The definition of weight maintenance. Int J Obes. 2006;30(3):391–9.  https://doi.org/10.1038/sj.ijo.0803175.CrossRefGoogle Scholar
  14. 14.
    Cunneen SA, Brathwaite CE, Joyce C, et al. Clinical outcomes of the REALIZE adjustable gastric band-C at 2 years in a United States population. Surg Obes Relat Dis. 2013;9(6):885–93.  https://doi.org/10.1016/j.soard.2013.02.009.CrossRefPubMedGoogle Scholar
  15. 15.
    Apovian CM, Shah SN, Wolfe BM, et al. Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial. Obes Surg. 2017;27(1):169–76.  https://doi.org/10.1007/s11695-016-2325-7.CrossRefPubMedGoogle Scholar
  16. 16.
    Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–6.  https://doi.org/10.2337/dc10-2415.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Horbach T, Thalheimer A, Seyfried F, et al. Abiliti closed-loop gastric electrical stimulation system for treatment of obesity: clinical results with a 27-month follow-up. Obes Surg. 2015;25(10):1779–87.  https://doi.org/10.1007/s11695-015-1620-z.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    McCarney R, Warner J, Iliffe S, et al. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7(1):30.  https://doi.org/10.1186/1471-2288-7-30.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Busetto L, Torres AJ, Morales-Conde S, et al. Impact of the feedback provided by a gastric electrical stimulation system on eating behavior and physical activity levels. Obesity (Silver Spring). 2017;25(3):514–21.  https://doi.org/10.1002/oby.21760.CrossRefGoogle Scholar
  20. 20.
    Guo X, Li Y, Yao S, et al. Parameter selection and stimulating effects of an adjustable gastric electrical stimulator in dogs. Obes Surg. 2014;24(1):78–84.  https://doi.org/10.1007/s11695-013-1037-5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • S. Morales-Conde
    • 1
  • I. Alarcón del Agua
    • 1
  • L. Busetto
    • 2
  • F. Favretti
    • 3
  • M. Anselmino
    • 4
  • G. M. Rovera
    • 5
  • M. Socas-Macias
    • 1
  • A. Barranco-Moreno
    • 1
  • R. Province-Azalde
    • 6
  • A. J. Torres
    • 7
  1. 1.Innovation and Minimal Invasive Surgery UnitHospital Virgen del RocioSevillaSpain
  2. 2.Department of Medicine – University of Padova, Center for the Study and the Integrated Management of ObesityClinica Medica 3 - Padova University HospitalPadovaItaly
  3. 3.Primari Vicenza Regional HospitalCasa di cura EreteniaVicenzaItaly
  4. 4.Bariatric Surgery DepartmentUniversity Hospital PisaPisaItaly
  5. 5.Clinica San Luca TorinoTorinoItaly
  6. 6.IntraPace Inc.San JoseUSA
  7. 7.Department of SurgeryHospital Clínico San Carlos. Hospital Universitario Madrid MonteprincipeMadridSpain

Personalised recommendations